Table 2.
Comparison of background characteristics between the patients with optimal response and suboptimal response
| Optimal response | Suboptimal response | |
|---|---|---|
| Age, years | ||
| Median | 57 | 71 |
| Range | 36–67 | 55–83 |
| Gender | ||
| Male | 1 | 1 |
| Female | 2 | 6 |
| Primary (colon/rectum) | ||
| 0 | 2 | |
| 3 | 5 | |
| RAS (wild/mutant) | ||
| wild | 2 | 3 |
| mutant | 1 | 4 |
| Performance status | ||
| 0 | 0 | 2 |
| 1 | 3 | 4 |
| 2 | 0 | 1 |
| No. of chemotherapy lines | ||
| 2 | 0 | 1 |
| 3 | 0 | 3 |
| 4 | 2 | 1 |
| 5 | 1 | 2 |
| Cycles of regorafenib | ||
| Median | 4 | 1 |
| Range | 1–15 | 1–3 |
| Reasons for discontinuation | ||
| Disease progression | 2 | 3 |
| Toxicity | 0 | 4 |
| Best response in RECIST | ||
| SD | 2 | 2 |
| PD | 1 | 5 |
| Best change in size | ||
| Median | + 16.0% | + 25.5% |
| Range | + 1.4% to + 31.5% | −6.2% to + 280.6% |
Abbreviations. SD stable disease, PD progressive disease